On or around 07/20/2017 (Ongoing date of last review)
Filing Date: July 20, 2017
According to the Complaint, it is alleged Defendants have violated Sections of the Exchange Act by causing a materially incomplete and misleading joint proxy statement/prospectus/information statement (the “Proxy”) to be filed with the SEC and disseminated to Jaguar shareholders. The Proxy recommends that Jaguar shareholders vote in favor of a Proposed Merger whereby Jaguar, in an all-stock transaction, will acquire Napo, with Jaguar continuing as the surviving entity (the “Proposed Merger”).
Company & Securities Information
Defendant: Jaguar Animal Health, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: JAGX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Tony Plant , et al. v. Jaguar Animal Health, Inc., et al.
COURT: N.D. California
DOCKET #: 17-CV-04102
JUDGE: Hon. Richard Seeborg
DATE FILED: 07/20/2017
CLASS PERIOD START: 07/06/2017
CLASS PERIOD END: 07/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·